NewSquare Capital LLC Acquires 105 Shares of Abbott Laboratories (NYSE:ABT)

NewSquare Capital LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 78.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 239 shares of the healthcare product maker’s stock after buying an additional 105 shares during the quarter. NewSquare Capital LLC’s holdings in Abbott Laboratories were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Impax Asset Management Group plc grew its stake in Abbott Laboratories by 0.5% during the third quarter. Impax Asset Management Group plc now owns 557,608 shares of the healthcare product maker’s stock valued at $63,573,000 after acquiring an additional 2,754 shares in the last quarter. United Advisor Group LLC purchased a new position in shares of Abbott Laboratories in the third quarter valued at $302,000. Balentine LLC raised its stake in Abbott Laboratories by 48.6% during the third quarter. Balentine LLC now owns 8,296 shares of the healthcare product maker’s stock valued at $946,000 after purchasing an additional 2,713 shares in the last quarter. Avidian Wealth Enterprises LLC lifted its position in Abbott Laboratories by 1.9% during the third quarter. Avidian Wealth Enterprises LLC now owns 8,213 shares of the healthcare product maker’s stock valued at $936,000 after purchasing an additional 157 shares during the last quarter. Finally, Beacon Financial Advisory LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth $201,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at $16,152,064.50. This trade represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,282 shares of company stock worth $3,263,348. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Trading Up 0.1 %

Shares of NYSE:ABT opened at $137.68 on Thursday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $238.79 billion, a PE ratio of 18.00, a P/E/G ratio of 2.52 and a beta of 0.75. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The business’s fifty day simple moving average is $124.51 and its 200-day simple moving average is $118.42.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $11.03 billion. During the same period in the previous year, the company posted $1.19 earnings per share. The firm’s revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.71%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wells Fargo & Company lifted their target price on Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, January 23rd. Evercore ISI increased their price target on Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Citigroup upped their price objective on Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group raised their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Barclays reissued an “overweight” rating and issued a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.19.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.